People on the Move Management Changes at Roche

Johannes (Hans) Clevers will succeed William Pao as Head of Roche Pharma Research and Early Development (pRED) and become a member of the company’s Corporate Executive Committee. Clevers who is currently a member of Roche’s Board of Directors will step down and make way for a new candidate which is yet to be announced.

Basel/Switzerland – Roche has recently announced that William Pao (1967), M.D., Ph.D., and Head of Roche Pharma Research and Early Development (pRED) since 2018, has decided to leave Roche for a new opportunity and return to the United States, effective March 18, 2022. Johannes (Hans) Clevers (1957), M.D., Ph.D., who joined the Board of Directors in 2019, will step down from this position and be appointed the new Head of Roche pRED effective March 18, 2022. Hans Clevers will become a member of the enlarged Corporate Executive Committee and will be based in Basel, Switzerland. A successor to Hans Clevers’ board position will be identified and announced at a later date.

Hans Clevers is Dutch and has his MS in Biology, M.D. and Ph.D. from the University of Utrecht in The Netherlands. He currently holds the posts of Professor in Molecular Genetics at University Utrecht, Principal Investigator at Hubrecht Institute as well as the Princess Máxima Center for Pediatric Oncology and Oncode Investigator. In addition, he serves on several scientific advisory boards including the Francis Crick Institute, and is a co-founder of several companies across the world. He is the recipient of multiple international awards and is a member of the Royal Netherlands Academy of Sciences, the National Academy of Science in the United States, Academy of Science in France, and The Royal Society in the UK.

(ID:47972003)